Rivaroxaban was associated with reduced systolic and diastolic blood pressure in retrospective clinical data and hypertensive mice, showing strong binding affinity for GIR (-10.6 kcal/mol).
Does rivaroxaban reduce blood pressure in experimental models and clinical cohorts?
Rivaroxaban demonstrates potential blood pressure-lowering effects through experimental and retrospective clinical validation, suggesting an added benefit for AF patients with hypertension.
Background Rivaroxaban is primarily utilized in patients with atrial fibrillation (AF) to decrease the risk of thrombosis. Drug repositioning strategies have been regarded as beneficial in identifying the potential effects of clinical drugs, and the current study was conducted to explore the potential blood pressure reduction effect of rivaroxaban. Methods A combination of machine learning models was employed to screen 3,285 non-antihypertensive drugs in the FDA database for potential antihypertensive effects. A comprehensive approach was adopted, encompassing retrospective clinical data analysis, animal experiments, and cell-based studies. This multifaceted strategy was employed to systematically assess the concordance between the outcomes of predictive models and the observed data. Results The machine learning predicted eight top non-antihypertensive drugs with pressure reduction effects. Next, the retrospective clinical data showed that the patients treated with Rivaroxaban were associated with greatly reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP). Meanwhile, it demonstrated that rivaroxaban inhibited Ang II-induced Vimentin and Col 1a mRNA levels in human umbilical vein endothelial cells (HUVECs), and reduced the migration of human vascular smooth muscle cell (HUVSCs) after Ang II stimulation in vitro . In vivo , Rivaroxaban also exhibited an obvious effect on pressure reduction in hypertensive mice. The molecular docking revealed that rivaroxaban primarily exhibited strong binding affinity for glucose-dependent insulinotropic receptor (GIR, -10.6 kcal/mol). Conclusions This approach provides a potential new option for patients with AF with hypertension, to ameliorate cardiovascular remodeling when selecting rivaroxaban as the oral anticoagulant. While further validation should be conducted to explore the detailed mechanism by which rivaroxaban regulates GIR in hypertension.
Kuang et al. (Mon,) conducted a other in Hypertension. Rivaroxaban was evaluated on Blood pressure reduction. Rivaroxaban was associated with reduced systolic and diastolic blood pressure in retrospective clinical data and hypertensive mice, showing strong binding affinity for GIR (-10.6 kcal/mol).